… Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized …
intra‐cellular protein inclusions highly enriched in aggregated α‐synuclein (αSyn), known as Lewy …

… of Parkinson's disease exist 2 , but only three of the mutant proteins are known. In familial
forms of Parkinson's disease linked to mutations in α-synuclein, … forms of Parkinson's disease, …

… , of these angles of alpha-synuclein toxicity. Here we review the current … disease-modifying
therapy by targeting the spread, production, aggregation, and degradation of alpha-synuclein. …

… α-synuclein burden and Parkinson's disease pathology has led to the hypothesis that α-synuclein …
that the aggregation of α-synuclein results in toxicity because of loss of necessary α-…

… be αsynuclein, and insoluble α-synuclein filaments were recovered from purified LBs [21,
22]. The production of wild type α-synuclein … Cells transfected with αsynuclein develop LB-like …

… Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a highly effective
symptomatic therapy for motor deficits in Parkinson's disease (PD). An additional, disease‐modifying …

… of Alzheimer's disease amyloid plaques NAC (4). The human α synuclein gene was …
Using this contig, we established that the α-synuclein gene is located within the D4S2371–…

Parkinson’s disease (PD) comprises a spectrum of disorders with differing subtypes, the
vast majority of which share Lewy bodies (LB) as a characteristic pathological hallmark. The …

… Mutations in the α-synuclein gene (SNCA) in the Contursi kindred (1) implicated this
gene in Parkinson's disease (PD). Subsequently, α-synuclein was identified as the major …

… α-synuclein appears to be delivered by unconventional exocytosis of intravesicular αsynuclein…
Compared to the cytosolic α-synuclein, intravesicular α-synuclein is prone to aggregation …